1. A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
- Author
-
Hoimes, Christopher, Flaig, Thomas, Milowsky, Matthew, Bilen, Mehmet, Gupta, Shilpa, Srinivas, Sandy, Merchan, Jaime, McKay, Rana, Petrylak, Daniel, Sasse, Carolyn, Moreno, Blanca, Yu, Yao, Carret, Anne-Sophie, Rosenberg, Jonathan, and Friedlander, Terence
- Subjects
enfortumab vedotin ,lay summary ,pembrolizumab ,plain language summary ,urothelial cancer ,Humans ,Urologic Neoplasms ,Antibodies ,Monoclonal ,Humanized ,Antibodies ,Monoclonal ,Carcinoma ,Transitional Cell ,Urinary Bladder Neoplasms - Abstract
WHAT IS THIS SUMMARY ABOUT?: This summary provides the results of a study of two treatments for cancer, enfortumab vedotin and pembrolizumab, that were studied together against locally advanced or metastatic urothelial cancer (la/mUC), a cancer that occurs most commonly in the bladder. WHAT WERE THE RESULTS?: In the 45 patients studied, around 16% did have serious side effects, but most side effects were manageable. Twenty-four percent of patients, however, stopped the study treatment because of their side effects. Within about 2 months of starting treatment, most patients (73%) tumors were smaller and stayed smaller, on average, for more than 2 years. WHAT DO THE RESULTS MEAN?: The combination of enfortumab vedotin plus pembrolizumab is a new treatment option for patients with locally advanced or metastatic urothelial cancer when they cannot receive the typical treatment, cisplatin. Advanced or metastatic urothelial cancer is a type of cancer where the cancer has already spread outside of the bladder or urinary tract.
- Published
- 2024